1. Addition of plerixafor in poorly mobilized allogeneic stem cell donors
   Lefan Zhuang et al, 2022, Journal of Clinical Apheresis CrossRef
2. Silybin suppresses cell proliferation and induces apoptosis of multiple myeloma cells via the PI3K/Akt/mTOR signaling pathway
   NAN FENG et al, 2016, Molecular Medicine Reports CrossRef
3. Successful “on‐demand” plerixafor for autologous peripheral blood stem‐cells transplantation for relapsed/refractory germ cell tumors
   Andrea Corbingi et al, 2022, Journal of Clinical Apheresis CrossRef
4. Plerixafor-aided Mobilization of Peripheral Blood Hematopoietic Stem Cells to Support Subsequent High-dose Chemotherapy After a Prior Autologous Transplant
   Evangelos Fergadis et al, 2020, Clinical Lymphoma Myeloma and Leukemia CrossRef
5. Plerixafor mobilization of peripheral blood hematopoietic progenitors to support further high-dose chemotherapy cycles in a patient with germ-cell tumor relapsing after previous tandem high-dose chemotherapy and hematopoietic cell transplantation
   Constantinos Miltiadous et al, 2017, Anti-Cancer Drugs CrossRef
6. Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era
   Anis A. Hamid et al, 2019, Clinical Genitourinary Cancer CrossRef
7. Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma
   Ga-Young Song et al, 2019, BMC Cancer CrossRef
8. Hematopoietic stem cell mobilization strategies to support high-dose chemotherapy: A focus on relapsed/refractory germ cell tumors
   Eleni Porfyriou et al, 2021, World Journal of Clinical Oncology CrossRef